Doug Drysdale

Absolutely thrilled to share this - I’m joining Natural MedTech as incoming Chair of the Board of Directors. Natural MedTech is an AI-forward biosynthetic manufacturing platform pioneering the next generation of safe, scalable, and accessible medicines. They’re accelerating proprietary drug discovery and building a category-defining biosynthetic manufacturing business with global reach - with the huge potential to solve Western reshoring priorities for APIs - all while delivering cGMP-compliant, high-quality therapeutics through cutting-edge biomanufacturing innovation. As Australia’s leader in this space, NMT is bringing real technological differentiation and onshored manufacturing strength to solve critical healthcare challenges. Huge respect to the Natural MedTech team - I’m thrilled to help accelerate this exciting mission. #Biosynthesis #AI #Biomanufacturing #Biotech #cGMP #Onshoring #APIs #Reshoring

Amazing to see this AI-Tech-Biology momentum

Try out a free preview of your own BoardMemo at katogen.com/board-memos

💡 Introducing Katogen BoardMemos™!! Asset or company due diligence still too often arrives as fragmented slides and surface-level analysis. Katogen BoardMemos™ changes that. We deliver board-ready, operator-encoded memoranda on regulatory, BD, IP, and payer strategy delivered as in-depth, structured, and formatted PDFs ready for Boards, Investors, and Deal Teams. See the depth for yourself in our just-released 59-page thematic BoardMemo “AI in the Boardroom,” the caliber of work that usually comes from $20–25k boutique consulting engagements. Thesis-driven. Primary-source citations. Critical-path mapping. Competitive framing. Strategic options. Forwardable narrative. All delivered as a true playbook PDF ready for your dataroom or board deck. The voice and judgment come from 2 decades in the CEO seat. Process: Share a short brief on your program. Receive your BoardMemo in minutes. Download the polished PDF. Standalone BoardMemo: $1,299 Unlimited annual access: $20,000 (contact sales) See the product and explore a free preview: link in comments below. #biotech #BusinessDevelopment #RegulatoryAffairs

For this week's Katogen Insights newsletter I am sharing an interview I recently had with Henry Winslow at Tricycle Day. Enjoy and maybe you should subscribe! linkedin.com/posts/dougdrys…

@C_Angermayer Congrats, Christian. Very cool.

What a great start to life as a public company for $ENHA last Friday. Up more than 20%. But this was only day one - we’re just getting started. Our motto, displayed on the façade of the New York Stock Exchange, captures it perfectly: You Know There's More 😈

Here’s the link to the full interview: tricycleday.com/p/doug-drysdale

This was a great conversation with Henry at Tricycle Day. linkedin.com/posts/henrywin…

@Jason These biometrics should be reimbursed for everyone. Imagine the health advantages and long term cost savings of this dataset.

Google Health/Fitbit vs Whoop is gonna be a heck of a fight $100-300 a year for these products is tiny price to pay for the massive gains you get from them If only doctors and medical record companies and these devices played nicely together Right now the best option is to simply “roll your own” solution Eightsleep, Function/superpower, Oura/whoop/fitbit, peptides, glps etc Healthcare is the place AI could turn its reputation around

I’m thrilled to be a member of the team at @NaturalMedTech . I’ve always been passionate about building resilient, innovative supply chains, and NMT is perfectly positioned to lead in one of the most critical areas facing the industry today. The U.S. (and much of the West) remains dangerously dependent on overseas sources for many strategic Active Pharmaceutical Ingredients (APIs). From antibiotics to oncology drugs and essential generics, we’ve seen the vulnerabilities exposed by pandemics, geopolitical tensions, and quality issues. Onshoring isn’t just nice-to-have - it’s a national security and public health imperative. But traditional chemical synthesis often makes it uneconomical due to high costs, complex multi-step processes, waste, and the need for specialized facilities. This is where NMT’s biosynthetic systems change the game. By engineering living factories, we can produce complex molecules directly through biosynthesis. This delivers: •Dramatically simplified manufacturing: Fewer chemical steps, mild aqueous conditions, and higher regio- and stereo-specific yields. •Flexible, scalable domestic production: Compact fermentation facilities that can be built faster and sited closer to U.S. demand centers. •Superior sustainability: Significantly lower solvent and energy use, reduced hazardous waste, and strong ESG alignment. •Enhanced security and quality: Complete traceability, rapid scale-up during shortages, and full control over critical medicines without long global supply chains. •Ability to tackle difficult molecules: Yeast excels at producing intricate, chiral structures that are costly or impractical via traditional chemistry. NMT is advancing its platform technology specifically for high-value strategic APIs. The approach has moved well beyond proof-of-concept - with proven commercial scalability and economics that now strongly favor onshoring for many priority molecules. I’m looking forward to working with the team to accelerate partnerships, scale key programs, and help deliver more secure, reliable pharmaceutical supply chains. The future of strategic API manufacturing isn’t just about bringing production home - it’s about harnessing engineered organisms to make it better, cheaper, and far more resilient than before.

@Zephyr_hg Ideas. Thanks for the posts.

50 AI businesses you could start this weekend. Pick one. Every idea comes with a revenue path, MVP scope, and exact tech stack so you're not guessing what to build or how it makes money. Organized into 5 categories: vertical agents, content tools, data infrastructure, edge AI, and services. Medical billing agents. Construction safety cameras. Prompt injection firewalls. Drone inspectors for solar farms. Each one scoped lean enough to validate in 48 hours with a simple ad or DM campaign. No more staring at tech trends trying to figure out where the money actually lives. Pick the lane that fits your skills and ship the tiniest possible version before your competition finds these ideas. Comment "IDEAS" and I'll DM it to you (must be following)

@bloggersarvesh Or……..@askOkara

keep calling me delusional...but I will keep repeating this.. Claude + SEO is going to make more businesses millionaires in 2026 than bitcoin ever did. don’t bookmark this if it crosses your timeline. just paste this entire thing into Claude. thank me later.

Let no to article at Pharma Focus Europe: pharmafocuseurope.com/articles/intel…

The current biopharma M&A environment reflects a market under pressure from a $300 billion patent cliff, shifting regulatory conditions, and intensifying competition across novel modalities. This article examines the structural forces driving deal activity, the concept of intelligent collaboration, and how information velocity has become a defining factor in successful biopharma transactions this year. Link in comments…

New @NaturalMedTech website at: naturalmedtech.com

Absolutely thrilled to share this - I’m joining Natural MedTech as incoming Chair of the Board of Directors. Natural MedTech is an AI-forward biosynthetic manufacturing platform pioneering the next generation of safe, scalable, and accessible medicines. They’re accelerating proprietary drug discovery and building a category-defining biosynthetic manufacturing business with global reach - with the huge potential to solve Western reshoring priorities for APIs - all while delivering cGMP-compliant, high-quality therapeutics through cutting-edge biomanufacturing innovation. As Australia’s leader in this space, NMT is bringing real technological differentiation and onshored manufacturing strength to solve critical healthcare challenges. Huge respect to the Natural MedTech team - I’m thrilled to help accelerate this exciting mission. #Biosynthesis #AI #Biomanufacturing #Biotech #cGMP #Onshoring #APIs #Reshoring

@boardyai Biosynthetic

Pitch me your company in 1 word.

Link to newsletter: linkedin.com/pulse/katogen-… via @LinkedIn

In this week's Katogen Insights Newsletter we dig into why so many product launches underperform expectations and what teams can do in the 12 months before launch to prepare better. Welcome your comments and thoughts...link to newsletter below...